264608-14-2

Upstream product

• 3963-62-0 2,2-Diphenylethylamine 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 20419-68-5 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
• 110-87-2 3,4-dihydro-2H-pyran 
• 5451-40-1 2,6 dichloropurine 

Downstream Products

• 264608-17-5 6-[(2,2-diphenylethyl)amino]-9-(tetrahydro-2H-pyran-2-yl)-9H-purine-2-carbonitrile 
• 264608-15-3 N-(2,2-diphenylethyl)-2-(methylsulfanyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 264608-18-6 6-[(2,2-diphenylethyl)amino]-9H-purine-2-carbonitrile 
• 884654-08-4 (2-chloro-9H-purin-6-yl)-(2,2-diphenyl-ethyl)-amine 
• 313345-13-0 6-[(2,2-diphenylethyl)amino]-9H-purine-2-carboxylic acid 
• 313345-09-4 6-[(2,2-diphenylethyl)amino]-9-(tetrahydro-2H-pyran-2-yl)-9H-purine-2-carboxylic acid 
• 313345-11-8 6-[(2,2-diphenylethyl)amino]-N-[2-(1-piperidinyl)ethyl]-9H-purine-2-carboxamide 
• 313345-14-1 ethyl 6-[(2,2-diphenylethyl)amino]-9-(tetrahydro-2H-pyran-2-yl)-9H-purine-2-carboxylate 
• 380222-94-6 9-{(3AR,4R,6S,6AS)-6-[(ethylamino)carbonyl]-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl}-6-[(2,2-diphenylethyl)amino]-N-{2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl}-9H-purine-2-carboxamide 
• 1360054-67-6 C₄H₁₁N*C₃₀H₃₂N₆O₆ 
• 380222-90-2 C₃₀H₃₁N₅O₇ 
• 1360054-66-5 N-(2,2-diphenylethyl)-2-(ethoxycarbonyl)-2',3'-O-isopropylidene-adenosine hydrogen sulfate 

Relevant academic research and scientific papers

Development of a scaleable process for the synthesis of the A2a agonist, UK-371,104

The development and utilization of a scaleable process for the manufacture of the A2a agonist UK-371,104 (1) is described. Key steps in the synthesis include (i) a palladium-catalyzed cyanation reaction to prepare the nitrile 10, (ii) a telescoped convers

Purine derivatives

The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds as adenosine A2a receptor agonists.

Purine derivatives

The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as adenosine A2a receptor agonists.

Purine derivatives

The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as adenosine A2a receptor agonists.

Purine derivatives

The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as adenosine A2a receptor agonists.

2-aminocarbonyl-9H-purine derivatives

The present invention relates to compounds of the formula. and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.

Purine derivatives

The present invention relates to the compounds of the formula: and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, composites containing, and the uses of such compounds as adenosine A2a receptor agonists.

Adenosine A2A receptor agonists as antiinflammatory agents

The present invention provides compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, together with processes for the preparation of, compositions containing, uses of and intermediates used in the preparation of such compounds that have A2a receptor agonist activity.